Vion Pharmaceuticals to Present at C. E. Unterberg, Towbin Life Sciences Conference

Strategic Insights -

Vion Pharmaceuticals, Inc. announced today that it will be making a corporate presentation at the C. E. Unterberg, Towbin Life Sciences Conference on Tuesday, October 31, 2006, at 4:00 p.m. EST. The presentation will focus on the company's commitment to developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials: Cloretazine(R) (VNP40101M) and Triapine(R). The company's pipeline also includes VNP40541, a hypoxia-selective compound, and hydrazone compounds.

Key Takeaways:

  • Vion Pharmaceuticals is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics.
  • The company has two agents in clinical trials: Cloretazine(R) (VNP40101M) and Triapine(R).
  • Cloretazine(R) (VNP40101M) is being evaluated in Phase III and Phase II pivotal trials in combination with cytarabine in relapsed acute myelogenous leukemia and as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia.
  • Additional trials of Cloretazine(R) (VNP40101M) are underway in pediatric brain tumors, small cell lung cancer, and in combination with temozolomide in hematologic malignancies.
  • Triapine(R) is being evaluated in clinical trials sponsored by the National Cancer Institute.
  • Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds in preclinical studies.
  • The company is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors.
  • Vion Pharmaceuticals is viable and operating with the capacity to expand its pipeline beyond the products mentioned during the conference.

Statistics:

  • Vion has two agents in clinical trials: Cloretazine(R) (VNP40101M) and Triapine(R).
  • Phase III trials have begun for Cloretazine(R) (VNP40101M) in combination with cytarabine in relapsed acute myelogenous leukemia.
  • Phase II pivotal trials have begun for Cloretazine(R) (VNP40101M) as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia.
  • Additional trials of Cloretazine(R) (VNP40101M) are underway in pediatric brain tumors, small cell lung cancer, and in combination with temozolomide in hematologic malignancies.
  • 5 clinical trials are ongoing for Triapine(R) in 2006.

Sources:

  • Vion Pharmaceuticals, Inc. press release, October 30, 2006, "Vion Pharmaceuticals to Present at C. E. Unterberg, Towbin Life Sciences Conference"
  • Vion Pharmaceuticals, Inc. website, http://www.vionpharm.com/ (accessed October 30, 2006)